Cibus

Phase A — Understand the business

Lens 1 · Company Overview

Cibus, Inc. (San Diego, CA; Nasdaq: CBUS) is an agricultural biotechnology company that develops gene-edited plant traits and licenses them to seed companies for a per-acre royalty. It is not a seed company and not a grower — it edits a customer's elite germplasm, hands it back, and collects a royalty when the seed company sells the resulting seed. The core platform is the Rapid Trait Development System (RTDS®), productized as the Trait Machine™ — a "standardized, end-to-end, semi-automated, high-throughput gene editing system" that the company claims can edit a target trait into a customer's germplasm in "as little as one year," vs. 12–16 years for transgenic/conventional trait development. Over 500 patents / patents-pending cover RTDS and its edited traits.

The business model is a royalty/IP-licensing model, deliberately asset-light on the commercialization side. The company likens it to how GMO traits (Bt, glyphosate tolerance) have earned developers ~$8B/yr in aggregate trait fees on 300M+ acres. The pitch: gene-edited (non-transgenic) traits dodge the regulatory/consumer headwinds that throttled GMOs, because regulators in the US, Canada, much of South America, the UK and (newly) the EU treat RTDS edits as equivalent to conventional breeding.

Priority program (the whole near-term thesis): Rice herbicide-tolerance (HT1 and HT3) traits, targeting an initial Latin America launch in 2027 and the US in 2028 per the 10-K (web sources now put the US slip to 2029 — see Lens 5). Management's headline: the two Rice HT traits alone carry "over $200.0 million in Estimated Potential Annual Addressable Royalties" across the US + Latin America at peak. Critical caveat baked into the company's own footnotes: "Potential Annual Addressable Royalties" = (management's peak-addressable-acre estimate) × (management's per-acre trait-fee assumption), and management explicitly labels these "illustrative" forward-looking estimates, not a forecast of revenue. This is a TAM, not a pipeline of signed dollars.

Secondary program: Sustainable ingredients — biofragrances (yeast-fermentation bio-rose etc.) and lauric oils, "partially partner-funded and/or supported," including a multi-year collaboration with Procter & Gamble (entered early 2023). Completed pre-commercial pilot runs for two biofragrance products in Q3 2025.

Customers/partners (named): Seven Rice partners in the US + Latin America. In Latin America (5 partners): Interoc, Fedearroz, CIAT/FLAR (Hybrid Rice Consortium HIAAL), Semillano, and Semillas del Huila. India go-to-market advisory: AgVayā (engaged Oct 2025). The post-period commercial anchor is Interoc — a non-binding LOI (Jan 2026) toward a definitive Latin America licensing/marketing agreement, with trait transfer into Interoc's rice seeds completed May 2026.

Corporate structure red flag (carried through the whole dossier): Cibus, Inc. is a holding company whose only material asset is its interest in Cibus Global, LLC (an "Up-C" structure). Its near-term revenue thesis is encumbered by a related-party Royalty Liability — see Lenses 9, 10 — under which 10% of essentially all "Subject Revenues" (product, license, sublicense, milestone) collected goes to "Royalty Holders" who include directors and director-affiliated entities, once a $50M trailing-12-month revenue threshold is crossed.

Lens 2 · Supply Chain

Cibus sits in an unusual spot: it is upstream IP, not a physical-goods manufacturer, so the "supply chain" is a trait-development and licensing chain, not a bill-of-materials.

Map (upstream → Cibus → end customer):

• Inputs: Customer elite germplasm (provided by seed-company partners under material-transfer agreements), proprietary RTDS reagents (oligonucleotides / ODM chemistry), single-cell tissue-culture models, and lab/greenhouse capacity. Cibus also runs an early-stage AI collaboration with Biographica to prioritize edit targets (initially Canola/WOSR disease resistance).
• Cibus (the choke point it is trying to own): the Trait Machine crop-specific platforms. Operational platforms today: Cassava, Canola, Flax, Peanut, Potato, Rice, Sugar Beet, Wheat — with Canola and Rice already used to edit customer germplasm. Soybean is the gap — a cell has been edited for the HT2 trait but the platform is not yet operational ("Progressing").
• Field trials & seed production: outsourced to third parties. This is a single-source-of-execution-risk node — Cibus explicitly relies on third parties to "conduct, monitor, support, and oversee field trials," and field trials "may take up to 2–3 years".
• Downstream: Seed-company licensees do the bulk-up, regulatory variety registration, and farmer sale. Cibus is "not involved in seed bulk-up or launch once a trait is transferred". For HT traits there is also a herbicide/chemistry provider who shares the trait fee — i.e. an HT trait is only valuable paired with a companion herbicide, which Cibus does not own.
• End user: the farmer, who pays a per-acre trait fee bundled into the seed price.

Named downstream chain (Rice, Latin America): Cibus → trait transfer → Interoc / Fedearroz / CIAT-FLAR / Semillano / Semillas del Huila (seed cos) → import-permitted field testing/production → Ecuadorian/Colombian rice farmers, 2027 target.

Chokepoints / single-source dependencies:

1. Operations are geographically concentrated — the company is consolidating to a single San Diego HQ (53,423 sq ft, lease to 2033) and winding down its Roseville, MN facility; a greenhouse lease runs to 2028. Damage/disruption at San Diego is now a concentrated single-point risk the 10-K flags explicitly.
2. Companion-herbicide dependency for the entire HT thesis (Cibus owns the tolerance trait, not the chemistry).
3. Customer conversion is the real chokepoint — a material-transfer agreement is not a commercial contract; seed companies are "generally not obligated… to advance toward commercialization". The pipeline is full of relationships that may never convert to a royalty.

Lens 3 · Competitive Advantages (moats)

The moat thesis is: a defensible, regulatory-advantaged, crop-agnostic trait-editing platform with a 500+ patent estate, that develops traits ~3–5× faster and cheaper than transgenic incumbents and — because RTDS edits are non-transgenic — is regulated like conventional breeding in most key geographies.

Where the moat is real:

• Regulatory positioning is the single strongest asset. As of the 10-K, 17 USDA-APHIS "not regulated" determinations on Cibus technologies; positive determinations in Canada, Argentina, Chile, Ecuador, UK PBO framework (live Nov 2025); three FDA pre-market meetings completed in 2025. This is genuinely hard-won and time-consuming for a competitor to replicate trait-by-trait.
• Platform breadth / crop-agnosticism. Eight operational crop platforms means Cibus can, in principle, drop any pipeline trait into any of those crops' elite germplasm — a real scope advantage vs. single-crop point solutions.
• Speed — claimed ~1-year edit-into-germplasm vs. 12–16 years transgenic — is the core value proposition to a seed-company partner.

Where the moat is weak or contested (the bear's foothold):

• No commercial proof of the moat. After 20+ years and an $858M accumulated deficit (Lens 5), the company has never earned royalty revenue — only collaboration/research fees ($3.6M FY2025). A moat you have never monetized is a hypothesis.
• Bargaining power is inverted. Cibus needs the seed companies more than they need Cibus — the seed cos own the germplasm, the channel, and the farmer relationship; Cibus is one of several gene-editing toolmakers courting them. The HT thesis also requires a herbicide partner. This is weak supplier/customer power.
• IP is not uncontested. Foundational CRISPR ag rights are licensed largely to Corteva; the EU NGT framework now requires NGT-1 applicants to disclose all patents into a public database and stands up an expert group to examine patent effects — a sign IP friction in the space is rising, not falling.
• Better-capitalized competitors (Lens 13): Inari (~$2.17B valuation, >$720M raised), Pairwise ($155M raised + a Corteva JV), Tropic Biosciences ($190M raised) are all private and far better funded than Cibus's ~$106M public market cap. Cibus is the distressed name in a field of well-funded peers.

Verdict on the moat: real on the science and regulatory axes, unproven on the commercial axis, and undermined by a capital position so weak that the company may be forced to license/sell the moat (strategic alternatives) before it can harvest it.

Lens 4 · Segments

Cibus has one operating and reportable segment — the CODM (the CEO) manages on a consolidated basis. There is no product-line or geographic P&L breakout in the financials, so a segments.csv-grounded table is n/a — single segment. What can be sourced:

• Revenue by type (all of it collaboration/research, none royalty): FY2025 total revenue $3.6M (−15% YoY from $4.3M), all from collaboration/contract-research agreements (Rice + Sustainable Ingredients); the company "has not yet begun earning royalty revenues".
• Geography: for Q1-FY2026 and Q1-FY2025, "all revenues from external customers were derived, and all long-lived assets were located, in the United States".
• Q1-FY2026 segment expense detail (the closest thing to a breakout): | Line (Q1-FY26, $000) | Q1-FY26 | Q1-FY25 | |---|---|---| | Revenue | 1,681 | 1,034 | | Personnel expenses | 5,788 | 6,761 | | Professional fees | 1,324 | 5,423 | | Stock-based comp | 1,571 | 2,499 | | Goodwill impairment | — | 20,950 | | Other segment expenses | 5,118 | 6,972 | | Total operating expenses | 13,801 | 42,605 |

The trend that matters: operating expense is decelerating hard (Q1-FY26 opex $13.8M vs. $42.6M a year ago) — but ~$22M of that drop is the prior-year goodwill impairment lapping; the cash opex decline is real but driven by restructuring, not growth. Revenue is up 62% YoY in Q1 ($1.68M vs $1.03M) but off a trivial base and still pre-royalty.

---

Phase B — Measure performance (·+clinical· swap)

Lens 5 · Pipeline by phase (swap for "Earnings Result")

The asset table is the company. Cibus's pipeline, with development status and economics as the company states them:

* Canola/Soybean programs are explicitly "subject to partner funding" — Cibus will not self-fund them. Also in the portfolio: Alfalfa (altered-lignin, FDA-cleared, divested to a seed-co partner), Light Leaf Spot (UK DEFRA LLS-ERASED consortium), Wheat (nitrogen-use-efficiency / disease / low-gluten — partner-funded only), plus dormant platforms in Cassava/Flax/Peanut/Potato/Sugar Beet.

The latest "print" (FY2025 10-K + Q1-FY2026 10-Q) — read as a development-stage scorecard, not an earnings beat:

Income statement (FY2025 vs FY2024):

Q1-FY2026 vs Q1-FY2025:

Q4-FY2025 specifically (per web, from the 8-K/press release): revenue $1.06M, MISSING the ~$1.68M consensus by ~37%; net loss $31.9M (incl. the $9.1M Roseville long-lived-asset impairment); EPS −$0.42 (beat the −$0.44 estimate by a penny); stock fell ~7% after-hours on the print.

Balance-sheet flags (the load-bearing part of this name):

• Cash $30.3M at 2026-03-31 (up from $9.9M at year-end — entirely financed, see below), against $13.9M current liabilities.
• Goodwill $232.5M = 72% of $324.2M total assets. Intangibles a further $31.2M. The "value" on the balance sheet is almost entirely the Cibus Global acquisition goodwill, already impaired by $21.0M (FY25) on top of $181.4M (FY24). A further stock-price-driven impairment is a live risk.
• Royalty liability (related party) $244.0M — the largest liability on the book, accreting at a 16.5% effective yield, +$9.1M of non-cash interest in Q1 alone.
• Total stockholders' equity $21.8M at FY-end (down from $92.2M a year prior).

Cash burn vs. target: operating cash burn was $50.6M FY2025 and $11.5M in Q1-FY2026 (≈ $46M annualized). Management's stated goal is to cut annual net cash usage to "$30.0 million or less during 2026" — but Q1 is running well above that pace, and the 10-Q concedes "these cost reduction initiatives alone will not be sufficient to forestall a cash deficit".

Guidance / outlook: No revenue guidance (pre-revenue). The one number management stands behind is the late-Q3-2026 cash runway (see Lens 11) and the $30M/yr burn target. Tone in filings is cautiously "inflection point" optimistic on the science, explicitly grim on liquidity ("substantial doubt … going concern").

Lens 6 · Earnings Calls / management focus (sentiment trend) (no transcripts on shelf → web-derived)

No transcripts are in transcripts/ (the ingest-transcript.ts sources don't scrape Cibus cleanly), so this lens is ``/summary-derived and lower-confidence than the filings lenses.

What management has been focused on, and how the message has shifted (FY2024 → mid-2026):

• 2024: "transformation" narrative post-Calyxt merger; first major goodwill impairment ($181M); first restructuring announced Q4-2024.
• Through 2025: a hard pivot to "streamlining" — the word recurs constantly. The story narrowed from a broad multi-crop platform vision to "Rice first, sustainable ingredients second, everything else only if a partner pays." Two RIFs (34 FTEs completed by Dec-2025; 15 more effective Mar-2026) and consolidation to San Diego.
• 2026: the message is now bifurcated — upbeat on regulatory/commercial milestones (EU NGT trilogue concluded Dec-2025; Interoc trait transfer May-2026; "on track for 2027 Latin America launch") and explicit on existential funding risk ("Board … continues to evaluate a full range of strategic alternatives to maximize shareholder value").

Recurring phrases: "industrializing breeding," "Future of Breeding™," "inflection point," "streamlined business focus," "potential annual addressable royalties," "partner-funded." What they've stopped saying: the expansive multi-crop simultaneous-development vision of 2023–24 — that has been quietly shelved in favor of Rice monomania driven by cash scarcity.

Sentiment read: management tone is defensively optimistic — leaning hard on regulatory wins (which are genuine) to offset a market that is pricing the balance sheet, not the pipeline. The "strategic alternatives" language is the tell: a board that has stood up a special committee to explore "business combinations, asset sales and licensing" is a board hedging against the stand-alone case failing.

Lens 7 · Catalyst calendar + peer/mechanism comps (swap for "Comps")

(a) Catalyst calendar — what de-risks or kills the thesis, and when:

(b) Mechanism comps — Cibus's Rice HT is not a monopoly mechanism. The competing non-GMO HT rice systems already on the market are the real comp set:

• Clearfield® (BASF) — imidazolinone-tolerant rice (mutated ALS), the incumbent.
• Provisia® / Max-Ace® (BASF) — ACCase-inhibitor-tolerant rice, the newer incumbent built to manage Clearfield-resistant weedy rice.
• Plus a wave of CRISPR/academic HT-rice efforts (glyphosate-EPSPS, paraquat-tolerance) globally, including ICAR's gene-edited rice already planted in India.

Cibus's pitch is that its HT traits are better/complementary weed-management chemistries delivered non-transgenically into elite germplasm — but it is entering a category with entrenched BASF systems, not an empty field.

(c) Valuation/peer table — equity comps. Multiples are largely n/a / not meaningful because Cibus is pre-revenue (no EV/EBIT, no P/E) and the closest peers are private (no public multiple). The honest comparison is capitalization, which is the whole point:

The comp table's message: Cibus is the only pure-play public gene-editing trait company of scale, but it is also the weakest-capitalized survivor in a field where the well-funded players are private and one direct peer (Benson Hill) already went bankrupt. P/E and EV/EBIT are n/a — pre-revenue, not sourced; equity multiples would be meaningless.

Lens 8 · Stock-Price Catalysts (what actually moves CBUS)

Over the post-merger life of the stock (Jun-2023 → Jun-2026), the price has collapsed from a post-merger/post-1-for-5-reverse-split base ($16+ implied) to **$1.40**, with a 52-week range of $1.09–$4.19 and roughly −90%+ over the trailing year. The pattern of >5% moves reveals what the market actually reacts to:

1. Dilution / financings (dominant driver, negative). Each follow-on (Jan-2025 $22.6M at $2.50; Jun-2025 $25.0M at $1.75; Jan-2026 $19.8M at $1.50; Mar-2026 $13.6M at $2.15) reset the stock lower; the 44% share-count increase in a year is the single biggest force on the price. CBUS trades as a financing-driven instrument, not a fundamentals-driven one.
2. Goodwill impairments / earnings prints (negative). The Q4-FY2025 print (revenue −37% vs consensus, $31.9M loss) dropped the stock ~7% after-hours.
3. Regulatory milestones (positive but fading). EU NGT trilogue progress, USDA-APHIS determinations, UK PBO go-live produced relief rallies — but the market increasingly discounts these because they don't fix the cash problem.
4. Commercial/partner news (positive, episodic). Interoc LOI and trait-transfer headlines drove pops.
5. Insider buying (mildly positive signal). Former CEO/Chairman Rory Riggs participated in essentially every raise (he is ~28% holder), which the market reads as a partial floor.

The tell: for CBUS, the market reacts to the financing calendar and the cash runway far more than to the pipeline. Good science news rallies fade; the next dilution headline dominates.

---

Phase C — Judge people & books

Lens 9 · Management

Leadership is mid-transition — and the freshest fact post-dates the filings:

• CEO: Craig Wichner became permanent CEO on June 8, 2026 — a Cibus board member only since Nov-2025, and founder/managing partner of Farmland LP (a ~$350M-AUM, ~19,000-acre US regenerative-farmland investment manager). His background is farmland investing and data-driven business models, not gene-editing R&D or large-cap ag-biotech operations. Appointing a farmland-fund founder (and recent board addition) as CEO of a going-concern trait-biotech is an unusual choice that reads as value-realization / strategic-alternatives oriented rather than scale-the-R&D oriented.
• President & COO + (former) Interim CEO: Dr. Peter Beetham — a genuine scientific founder who co-invented ODM gene editing 20+ years ago, founding member of the management team, instrumental in developing RTDS. He ran the company as Interim CEO from Feb-2025 until Wichner's appointment, and his 2026 base salary was cut from $650K to $585K on the role change. Other key scientific execs: Dr. Greg Gocal (CSO/EVP, founding member) and Noel Sauer.
• Founder / largest shareholder: Rory Riggs — co-founder; CEO Oct-2021→Feb-2025; Chairman until Aug-6-2025; co-founder of Royalty Pharma and FibroGen. He is the ~28% holder and bought into every dilutive raise. Chairman is now Mark Finn (Vantage Consulting; life-sciences-investment background).

(1) Track record: the scientific founders (Beetham/Gocal) have a real, decades-long record of building the RTDS platform and winning 17 USDA determinations — a credible science track record. The commercial/capital track record is poor: 20+ years, $858M cumulative deficit, zero royalty revenue, two big goodwill write-offs, and a stock down ~90%+.

(2) Tenure & skin in the game: founders are long-tenured; insider ownership is high (Riggs ~28%, and he keeps writing cheques into the raises) — a genuine alignment positive, though it also concentrates control. Equity-plan overhang: 2.8M options/RSUs/RSAs outstanding (weighted-avg strike $30.25 — i.e. legacy options are deeply underwater) plus an annual evergreen top-up of up to 7.5% of shares to the 2017 Plan.

(3) Capital allocation: dominated by survival financing — serial dilutive raises at ever-lower prices. The one disciplined move is the aggressive cost-cut/streamlining (burn target halved). The structural problem (below) is not of current management's making but encumbers them.

(4) Red flags: the related-party Royalty Liability is the headline governance flag — directors/affiliates are entitled to 10% of essentially all future revenue once $50M trailing revenue is hit (see Lens 10). A CEO who is a recent board member from outside the field plus an active strategic-alternatives committee signals the board may be steering toward a sale/licensing outcome rather than a stand-alone build.

(5) Founder vs. professional manager: a hybrid — scientific founders (Beetham/Gocal) still run the lab; the new CEO (Wichner) is an investor-operator installed to "accelerate growth and value creation" (read: monetize). For a cash-starved platform, that archetype usually presages a transaction.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst. Every figure labeled.

Income statement:

• No product/royalty revenue after 20+ years. All $3.6M FY2025 revenue is collaboration/research; "has not yet begun earning royalty revenues". Revenue-recognition risk is low because there is almost no revenue — but the forecasted-trait-revenue assumptions that drive the Royalty Liability were flagged by the auditor (Deloitte) as a Critical Audit Matter for "subjectivity and judgment" in trait-fee and adoption-rate assumptions.
• Non-GAAP flatter: SBC was $8.2M FY2025 (down from $10.75M) — material but declining; not used to manufacture a misleading "adjusted profit," since the company doesn't headline one.

Balance sheet:

• Goodwill is 72% of assets ($232.5M / $324.2M) and has already been impaired $21.0M (FY25) + $181.4M (FY24). The carrying value is an artifact of the 2023 Cibus Global acquisition accounting, not realizable cash. Further impairment is explicitly a live risk tied to the depressed stock price.
• The $244.0M related-party Royalty Liability is the most important forensic item. It is a fair-value, non-cash-accreting obligation at a 16.5% effective yield to "Royalty Holders" that include directors and director-affiliated entities. It (a) is a related-party transaction of unusual scale, (b) sits senior via an IP-security agreement over substantially all of Cibus Global's IP, and (c) means 10% of the first dollars of real revenue route to insiders, off the top, once the $50M trailing-12-month threshold trips. This both subordinates common holders and creates a built-in drag on the very revenue ramp the bull case depends on.
• Tax Receivable Agreement (TRA) liabilities to "TRA Parties" — another related-party value-leakage channel flagged in the risk factors.

Cash-flow statement:

• Cash burn ($50.6M FY25 operating) vastly exceeds revenue ($3.6M) — the company is ~93% financed by external capital, not operations. Financing inflows $46.6M FY2025 are the only reason it is a going concern.
• Cash flow does not diverge suspiciously from earnings in a fraud sense — the gap is impairments and royalty-liability accretion (both clearly disclosed non-cash) — but the dependence on continuous equity issuance is the structural cash-flow red flag.

Going concern: Explicit substantial-doubt going-concern qualification in both the 10-K and 10-Q — the single most important forensic flag. Auditor: a CAM around the Royalty Liability, but no going-concern adjustment and no restatement.

Regulatory & legal findings (required sub-section):

• SEC enforcement: None. Verified via SEC EDGAR EFTS — 0 Litigation Releases and 0 AAERs naming Cibus since 2021-06-30.
• 10-K Item 3 (Legal Proceedings): "The Company was not a party to any material pending legal proceedings as of December 31, 2025.". (Note: FY2025 SG&A absorbed a $2.6M repayment of previously-awarded insurance proceeds following an adverse Ninth Circuit decision on a prior litigation matter — a closed item, not pending.)
• Securities-bar solicitation: A plaintiff firm (Levi & Korsinsky) has publicized an "investigation" into potential securities-law violations. As of this dossier this is a solicitation/investigation, not a filed class action — common for any beaten-down microcap; no merits established.
• Non-SEC agencies (FTC/DOJ/FDA): no material enforcement actions found; FDA interactions are favorable (pre-market meetings, alfalfa clearance), not enforcement.
• Net: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), 10-K Item 3, and web search as of 2026-06-30. The forensic risk here is financial/structural (going concern + related-party royalty), not legal/enforcement.

---

Phase D — Project & stress-test

Lens 11 · Forward outlook — runway-to-catalyst + rNPV (swap for "EPS projection")

The question that actually matters for a pre-revenue, going-concern name is NOT three-year EPS — it is: does cash reach the next value-inflection catalyst? The answer today is no, not without another raise.

Runway math:

• Cash 2026-03-31: $30.3M.
• Q1-FY2026 operating burn: $11.5M (≈ $46M/yr run-rate); management targets ≤$30M/yr.
• Management's own stated runway (10-K): existing cash + the Jan-2026 raise funds operations "into late in the third quarter of 2026". The Mar-2026 raise ($13.6M) extends that modestly, but the 10-Q reiterates substantial-doubt going concern and that cost cuts "alone will not be sufficient".
• Conclusion: even on the optimistic $30M burn target, ~$30M cash ≈ ~12 months; on the actual Q1 pace, ~8 months → a wall around Q4-2026/Q1-2027, before the 2027 first-royalty catalyst. The first commercial Rice launch (2027, via Interoc) is on the far side of the cash wall. Another financing (or a partner/strategic-alternatives cheque) is required to bridge to first revenue — this is close to a certainty, and it is dilutive.

Revenue ramp (illustrative ``, NOT a forecast): Even if the 2027 LatAm launch lands on schedule, royalty revenue in 2027–2028 would be a fraction of the >$200M peak TAM — peak is "several years after commercial availability" by the company's own definition. A plausible-but-unsourced ramp is low-single-digit-$M of royalty in 2027–28 building over years — and the first ~$50M of trailing revenue triggers the 10% royalty-holder waterfall and the threshold to start paying it. The path to the common holder seeing free cash flow is long and structurally taxed.

rNPV sketch (lead asset = Rice HT, ``, illustrative only): peak addressable royalty ~$200M (US+LatAm) × a charitable ~25–40% probability-of-commercial-success for a never-commercialized-trait company × a high discount rate (going-concern, ~20%+) × multi-year ramp delay → a risk-adjusted lead-asset value plausibly in the low-to-mid-hundreds-of-$M before subtracting the $244M royalty liability and ongoing dilution. The $106M market cap is not obviously mispriced against that once the related-party liability and financing dilution are netted — the market is pricing the structure, not just the science. (Every input here is an unsourced estimate; do not treat as a valuation.)

No forecast.ts create logged — per --watchlist rules, and because the honest "base case" here is a binary (does it bridge to 2027 revenue without a death-spiral raise?), not a committed EPS line. The forecast worth tracking, if promoted: "CBUS executes a definitive Interoc commercial licensing agreement before 2026-12-31" and "CBUS raises additional equity before 2026-12-31" (the latter near-certain).

Lens 12 · Bull vs Bear

Bull case. Cibus owns a regulatory-advantaged, crop-agnostic gene-editing trait platform at the exact moment the global regulatory regime is flipping in its favor — US (17 USDA determinations), Canada, South America, UK PBO (live), and now the EU NGT framework formally adopted (2026). Its priority Rice HT program has cleared edits, greenhouse and field trials, has seven seed-company partners, a named commercial anchor (Interoc) with trait already transferred, and a 2027 first-launch line of sight into a >$200M peak-royalty TAM — with Canola, Soybean, India/Asia Rice as free options on top. The cost base has been halved via restructuring, the founder owns ~28% and keeps funding it, and at a ~$106M market cap the equity is a cheap call option on the first-ever gene-edited HT-rice royalty stream. If the 2027 launch converts and a partner funds the non-Rice pipeline, today's price looks like a generational entry on the "Future of Breeding."

Bear case. This is a 20-year-old, $858M-cumulative-deficit company that has never earned a dollar of royalty revenue and carries an explicit going-concern qualification, burning ~$46M/yr against $30M of cash — i.e. it does not have the money to reach its own 2027 catalyst and will dilute again (44% share growth in the last year; the entire price history is a financing-driven downtrend). Worse, the balance sheet is 72% goodwill (already impaired twice) and is encumbered by a $244M related-party Royalty Liability that skims 10% off the top of the first real revenue and is secured against substantially all the IP — so even success accrues heavily to insiders and creditors, not common holders. The flagship Rice HT trait faces entrenched BASF systems (Clearfield/Provisia) and far-better-funded private peers (Inari $2.17B, Pairwise, Tropic), the EU NGT rules explicitly exclude herbicide-tolerance from the easy lane, and the board has stood up a strategic-alternatives committee — a tell that the stand-alone case may not work.

Pre-mortem (18 months out, thesis broke — what happened?): Most likely path: the 2027 Interoc launch slips or arrives sub-scale; the company is forced into one or more highly dilutive raises at sub-$1.50 (or a reverse split to keep Nasdaq listing), the share count balloons, a strategic-alternatives outcome (fire-sale licensing or a cheap acquisition) caps the equity, and common holders are largely wiped while the royalty-holders and the new financing capture the residual value. A secondary path: another stock-price-driven goodwill impairment craters book equity and triggers covenant/listing problems.

Are multiples too high? Multiples are n/a (pre-revenue). The relevant question — is the ~$106M cap too high vs. risk-adjusted asset value net of the $244M royalty liability and forward dilution — is genuinely two-sided; this is not an obvious short or an obvious long.

Contrarian view (what the market may be refusing to see): The market is pricing CBUS as a dilution-death-spiral microcap and largely ignoring that the regulatory thesis it was built on has now actually come true (EU adopted; UK live; US settled). If — and it is a big if — a deep-pocketed strategic (a Corteva/BASF/Syngenta or a sovereign/India play) decides the cheapest way to own a validated, 500-patent, multi-crop non-transgenic trait platform is to buy Cibus outright rather than out-license, the strategic-alternatives process could deliver a takeout premium to a stock the market has left for dead. The same "strategic alternatives" language that reads as desperation could equally be the setup for an M&A exit. That optionality is the only reason this is WATCHING rather than BEARISH.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• Structural break in how it makes money: it has never made money this way. The entire revenue model is prospective and gated behind (a) seed companies choosing to commercialize traits they are "not obligated" to advance, and (b) a companion-herbicide economic split Cibus doesn't control. A 20-year-old platform with zero royalty revenue is the base-rate definition of a model that hasn't been proven to work.
• Revenue concentration / fragility: the near-term thesis is ~all-Rice, and within Rice, ~all-Interoc/LatAm. A single partner slipping or a single Latin American regulatory/agronomic setback resets the timeline past the cash wall.
• The moat may be weaker than bulls think: non-transgenic HT rice already exists (BASF Clearfield/Provisia, ICAR's gene-edited rice in India); CRISPR ag IP is concentrated in Corteva; and the best-funded gene-editing peers (Inari, Pairwise, Tropic) are private and could out-execute. Cibus's edge is regulatory timing and patent breadth, not an unassailable technical monopoly.
• Most dangerous competitor bulls underestimate: Corteva (and BASF in rice specifically) — incumbents with the channel, the germplasm, the herbicides, and CRISPR rights. If they decide gene-edited HT rice matters, Cibus is a price-taker.
• Worst capital-allocation / governance: the related-party Royalty Liability (10% of revenue to directors/affiliates, secured over the IP) and the TRA — both siphon value from common holders to insiders. Combined with serial sub-$2.50 dilution and deeply underwater legacy options ($30.25 strike), the incentive structure has not protected outside shareholders.
• Assumptions that must hold for today's price: that the company bridges to 2027 revenue without a death-spiral raise, that Interoc converts to a real contract, that royalties ramp fast enough to matter before the $50M royalty-holder waterfall and ongoing dilution eat the upside, and that no further goodwill impairment craters book equity. That is a lot of "ands."
• If growth disappoints by 20–30% (here: if the 2027 launch slips a year or arrives sub-scale): the cash wall is hit first, forcing dilution that mechanically compresses per-share value regardless of TAM — the valuation is dilution-elastic, not growth-elastic, at this stage.
• Single scenario that permanently impairs the business: a failed/again-delayed 2027 launch coinciding with a closed financing window → forced fire-sale of the IP under the strategic-alternatives process (the royalty-holders' IP security interest gives them leverage in any such sale) → common equity substantially impaired. Plausibility: moderate and rising the longer first revenue is delayed.

Lens 14 · Management Questions (ordered by information value)

1. Bridge to 2027: Exactly how many months of runway do you have at the actual Q1 burn pace, and what is the specific financing or partnership plan to bridge to first Rice royalty revenue without another dilutive equity raise below the current price?
2. Strategic alternatives: What is the special committee's mandate and timeline — is a sale or whole-company licensing of the platform on the table, and at what stage is that process?
3. Royalty Liability: Will the 10% related-party royalty waterfall be renegotiated, bought out, or subordinated before first revenue — and if not, how do common holders capture upside when 10% of revenue routes to directors off the top and the IP is pledged as security?
4. Interoc: What are the economic terms (trait fee, acreage commitment, exclusivity, minimums) of the contemplated definitive Interoc agreement, and when does it sign?
5. CEO mandate: Craig Wichner comes from farmland investing, not ag-biotech operations — was he hired to scale the company or to engineer a transaction? What does the board expect him to deliver in 12 months?
6. Burn target credibility: Q1 ran ~$46M annualized vs. the ≤$30M/yr target — what specific further cuts get you to $30M, and do they impair the Rice program's launch timeline?
7. Goodwill: At what stock price / fair-value level does the remaining $232.5M goodwill take another impairment, and what would that do to book equity and Nasdaq compliance?
8. EU NGT: Given herbicide-tolerance traits are excluded from the easy NGT-1 lane (they fall into GMO-equivalent NGT-2), what is the realistic European opportunity for your flagship Rice HT program, vs. only the disease/PSR traits?
9. Partner funding: The entire Canola/Soybean/Wheat pipeline is "subject to partner funding" — do you have signed partner funding for any of it today, or are these options contingent on capital you don't have?
10. Companion herbicide: Who supplies the herbicide your Rice HT traits are paired with, what is the trait-fee split, and is that relationship contractually secured?
11. Customer conversion: Of the seven Rice "partners," how many have moved past a material-transfer agreement to a binding commercial term sheet?
12. Nasdaq listing: Is a reverse split contemplated to maintain the $1.00 bid-price requirement, and what is the trigger?
13. Soybean: What concretely remains before the Soybean platform is "operational," and is it funded?
14. Insider participation: Will Rory Riggs (and other insiders) continue to backstop future raises, and at what point does insider participation create control/related-party concerns for outside holders?
15. The 20-year question: RTDS is 20+ years old with zero royalty revenue to date — what specifically is different now (beyond regulation) that makes you confident the licensing model finally converts to durable royalties?

---